RecruitingPhase 2NCT06592274
A Phase 2 Study of HB0017 in Psoriasis Patients
A Multicenter, Randomized, Double-blind Phase 2 Clinical Study Evaluating the Efficacy and Safety of Different Administration Regimens of HB0017 Injection in Patients With Moderate to Severe Plaque Psoriasis
Sponsor
Huabo Biopharm Co., Ltd.
Enrollment
200 participants
Start Date
Sep 30, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
This study is a randomized, double-blind phase 2 clinical trial aimed at exploring the efficacy, safety, and immunogenicity of HB0017 injection with different dosing regimens in the treatment of moderate to severe plaque psoriasis in subjects
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria5
- Male or female subjects aged 18-75 years (inclusive)
- Chronic plaque psoriasis (PSO) for at least 6 months prior to the randomization.
- Psoriasis Area Severity Index (PASI) \>=12 and body surface area (BSA) affected by PSO \>=10% and Static Physician Global Assessment (sPGA) score \>=3.
- Subjects who are suitable for systemic treatment or phototherapy for psoriasis as judged by the investigator
- Subjects who are able to use effective contraception from the screening period to 6 months after the last dose
Exclusion Criteria8
- Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic and/or guttate psoriasis) at screening or baseline Drug-induced psoriasis
- Ongoing use of prohibited treatments
- Any active infection (other than common cold) within 14 days
- Serious infection defined as requiring hospitalization or iv anti-infective(s) within 1 month prior to randomization
- Have previously received any drug that directly targets IL-17 or IL-17 receptor
- Have concurrent or recent use of any biologic agent within the following washout periods: etanercept \<28 days; infliximab and adalimumab \<60 days; golimumab \< 90 days; anti-IL-12/anti-IL-23 or anti-IL-23p19 antibody drugs \<6 months; or other anti-psoriatic therapy not listed herein within its 5 half-lives prior to randomization
- A history of inflammatory bowel disease or other serious autoimmune disease
- Previously diagnosed with serious mental illness such as anxiety, depression or suicidal tendency
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALHB0017
300mg Q12W
BIOLOGICALHB0017
300mg Q8W
BIOLOGICALHB0017
150mg Q4W
Locations(18)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06592274
Related Trials
Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis
NCT074019921 location
Impact of Tildrakizumab on Patient Reported Outcomes in Patients With Moderate-to-severe Psoriasis in Canada
NCT073707666 locations
Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis
NCT069823523 locations
Physician- vs Questionnaire-Based Screening for Psoriatic Arthritis in Psoriasis
NCT072982651 location
A Pilot Study to Assess How Safe and Effective Oral Roflumilast is for Treating Moderate to Severe Psoriasis in Adults
NCT072332911 location